Lates News

China Biologic Pharmaceuticals announced that the Phase III clinical trial of Leflunomide for the treatment of moderate to severe cGVHD is currently in the patient recruitment stage. The group will accelerate the global clinical development of Leflunomide to provide better treatment options for patients worldwide as soon as possible.